Molecular Biology Reports

, Volume 39, Issue 12, pp 10997–11004 | Cite as

Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer

  • Ning Shao
  • Ninghan Feng
  • Yang Wang
  • Yuanyuan Mi
  • Tian Li
  • LiXin HuaEmail author


Evidence is accumulating that cyclooxygenase-2 (COX-2) may play an important role in prostate cancer (PCa). Recently, gene polymorphisms in COX-2 have been implicated to alter the risk of PCa and overexpression of COX-2 may be associated with clinical and prognostic significance in PCa. However, the results of these studies are inconclusive or controversial. To derive a more precise estimation of the relationships, we performed an updated meta-analysis. A comprehensive search was conducted to examine all the eligible studies of COX-2 polymorphism and expression in PCa. We used odds ratios (ORs) to assess the strength of the association and the 95 % confidence intervals (CIs) give a sense of the precision of the estimate. Overall, no significant associations between COX-2 polymorphism and PCa risk were found. However, high expression of COX-2 was significantly higher in T3–T4 stages of PCa than in T1–T2 stages of PCa (OR = 2.33, 95 %CI: 1.54–3.53, P < 0.0001). COX-2 might play an important role in the progress of PCa, overexpression of COX-2 correlates with T3–T4 stages of PCa. COX-2 might be a potential therapy target for PCa and work as a prognostic factor for PCa patients.


COX-2 Polymorphisms Expression Prostate cancer Meta-analysis 



This study was supported by National Natural Science Foundation of China (Grant No.81272831), Natural Science Foundation of Jiangsu Province (BK2010577), Jiangsu Province’s Outstanding Medical Academic Leader program (RC201178), Six-Kinds-of-Top-Talent Program of Jiangsu Province (2011) and the Key Program of Jiangsu Province Geriatric Institute (Grant No.LK201101).

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

11033_2012_2001_MOESM1_ESM.doc (32 kb)
Supplementary material 1 (DOC 32 kb)
11033_2012_2001_MOESM2_ESM.tif (59 kb)
Supplementary material 2 (TIFF 58 kb)


  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A, Cancer statistics 2011 (2011) The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedCrossRefGoogle Scholar
  2. 2.
    McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V et al (2007) Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57(4):190–205PubMedCrossRefGoogle Scholar
  3. 3.
    Chowdhury S, Burbridge S, Harper PG (2007) Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61(12):2064–2070PubMedCrossRefGoogle Scholar
  4. 4.
    Schaid DJ (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13 Spec No 1:R103–R121PubMedCrossRefGoogle Scholar
  5. 5.
    Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ et al (2010) Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 202(2):76–81PubMedCrossRefGoogle Scholar
  6. 6.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85PubMedCrossRefGoogle Scholar
  7. 7.
    Pairet M, Engelhardt G (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 10(1):1–17PubMedCrossRefGoogle Scholar
  8. 8.
    Aparicio Gallego G, Diaz Prado S, Jimenez Fonseca P, Garcia Campelo R, Cassinello Espinosa J, Anton Aparicio LM (2007) Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol 9(11):694–702PubMedCrossRefGoogle Scholar
  9. 9.
    Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999) Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31(5):551–557PubMedCrossRefGoogle Scholar
  10. 10.
    Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B et al (2002) Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 22(4):2089–2096PubMedGoogle Scholar
  11. 11.
    Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58(19):4245–4249PubMedGoogle Scholar
  12. 12.
    Pruthi RS, Derksen E, Gaston K (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169(6):2352–2359PubMedCrossRefGoogle Scholar
  13. 13.
    Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F et al (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25(6):961–966PubMedCrossRefGoogle Scholar
  14. 14.
    Zhu W, Wei BB, Shan X, Liu P (2010) 765G > C and 8473T > C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37(1):277–288PubMedCrossRefGoogle Scholar
  15. 15.
    Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD et al (2010) Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol 184(3):842–850PubMedCrossRefGoogle Scholar
  16. 16.
    Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97(4):557–561PubMedCrossRefGoogle Scholar
  17. 17.
    Barba M, Yang L, Schunemann HJ, Sperati F, Grioni S, Stranges S et al (2009) Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res 28:135PubMedCrossRefGoogle Scholar
  18. 18.
    Lukiw WJ, Bazan NG (2000) Neuroinflammatory signaling upregulation in Alzheimer’s disease. Neurochem Res 25(9–10):1173–1184PubMedCrossRefGoogle Scholar
  19. 19.
    Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM et al (2009) Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27(30):4986–4993PubMedCrossRefGoogle Scholar
  20. 20.
    Denkert C, Thoma A, Niesporek S, Weichert W, Koch I, Noske A et al (2007) Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate 67(4):361–369PubMedCrossRefGoogle Scholar
  21. 21.
    Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11(9):3250–3256PubMedCrossRefGoogle Scholar
  22. 22.
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1):73–78PubMedCrossRefGoogle Scholar
  23. 23.
    Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO et al (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the cancer prostate in Sweden study. Cancer Res 64(8):2918–2922PubMedCrossRefGoogle Scholar
  24. 24.
    Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L et al (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 97(7):525–532PubMedCrossRefGoogle Scholar
  25. 25.
    Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190(3):279–286PubMedCrossRefGoogle Scholar
  26. 26.
    Xu S, Gao JP, Zhou WQ (2008) Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer. Zhonghua Nan Ke Xue 14(11):1031–1034PubMedGoogle Scholar
  27. 27.
    Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y et al (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157(1):29–35PubMedCrossRefGoogle Scholar
  28. 28.
    Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA et al (2002) Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118(2):194–201PubMedCrossRefGoogle Scholar
  29. 29.
    Ioannidis JP (1998) Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279(4):281–286PubMedCrossRefGoogle Scholar
  30. 30.
    Dickersin K, Min YI, Meinert CL (1992) Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267(3):374–378PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Ning Shao
    • 1
  • Ninghan Feng
    • 2
  • Yang Wang
    • 2
  • Yuanyuan Mi
    • 2
  • Tian Li
    • 3
  • LiXin Hua
    • 2
    Email author
  1. 1.Department of UrologyJiangsu Province Geriatric HospitalNanjingChina
  2. 2.Department of UrologyFirst Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  3. 3.Department of RespiratoryNanjing Chest HospitalNanjingChina

Personalised recommendations